MX2020002544A - Sales de glicopirrolato. - Google Patents

Sales de glicopirrolato.

Info

Publication number
MX2020002544A
MX2020002544A MX2020002544A MX2020002544A MX2020002544A MX 2020002544 A MX2020002544 A MX 2020002544A MX 2020002544 A MX2020002544 A MX 2020002544A MX 2020002544 A MX2020002544 A MX 2020002544A MX 2020002544 A MX2020002544 A MX 2020002544A
Authority
MX
Mexico
Prior art keywords
salts
glycopyrrolate
topicals
formulations
glycopyrrolate salts
Prior art date
Application number
MX2020002544A
Other languages
English (en)
Inventor
Patricia Andres
John Allan Statler
Anthony Adrian Shaw
Delphine Caroline Imbert
Jennifer Leigh Nelson
Lisa Lynn Mcqueen
Stephan Xander Mattheus Boerrigter
Jon Gordon Selbo
Mark Christopher Andres
Original Assignee
Dermira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51428856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020002544(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/024,484 external-priority patent/US8859610B2/en
Application filed by Dermira Inc filed Critical Dermira Inc
Publication of MX2020002544A publication Critical patent/MX2020002544A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describen sales de glicopirrolato que incluyen formas sólidas y formulaciones tales como preparaciones tópicas de las mismas; se describen métodos para obtener sales de glicopirrolato, que incluyen formulaciones tales como preparacionestópicas de las mismas, y métodos de tratamiento de la hiperhidrosis con sales de glicopirrolato, y formulaciones tales como preparaciones tópicas de las mismas.
MX2020002544A 2013-02-28 2015-08-27 Sales de glicopirrolato. MX2020002544A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361770920P 2013-02-28 2013-02-28
US201361770925P 2013-02-28 2013-02-28
US14/024,484 US8859610B2 (en) 2013-02-28 2013-09-11 Crystalline glycopyrrolate tosylate
US14/024,480 US9006461B2 (en) 2013-02-28 2013-09-11 Crystalline glycopyrrolate tosylate

Publications (1)

Publication Number Publication Date
MX2020002544A true MX2020002544A (es) 2020-07-20

Family

ID=51428856

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015011228A MX2015011228A (es) 2013-02-28 2014-02-28 Sales de glicopirrolato.
MX2020002544A MX2020002544A (es) 2013-02-28 2015-08-27 Sales de glicopirrolato.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015011228A MX2015011228A (es) 2013-02-28 2014-02-28 Sales de glicopirrolato.

Country Status (13)

Country Link
US (4) US9610278B2 (es)
EP (3) EP3842419B1 (es)
JP (2) JP6114841B2 (es)
KR (4) KR20150119468A (es)
CN (1) CN105026369A (es)
AU (2) AU2014223172B2 (es)
CA (1) CA2902795C (es)
ES (2) ES2981043T3 (es)
IL (3) IL317757A (es)
MX (2) MX2015011228A (es)
NZ (1) NZ710740A (es)
SG (1) SG11201506789PA (es)
WO (1) WO2014134510A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2671874T3 (es) 2007-10-18 2018-06-11 Rose U, Llc Formulaciones tópicas de glicopirrolato
US20220233500A1 (en) * 2014-08-29 2022-07-28 Journey Medical Corporation Glycopyrrolate salts
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
US9926270B2 (en) 2014-08-20 2018-03-27 Dermira, Inc. Process for production of glycopyrronium tosylate
WO2016033313A1 (en) * 2014-08-27 2016-03-03 Dermira, Inc. Hyperhidrosis treatment
CN107915666A (zh) * 2016-10-09 2018-04-17 四川海思科制药有限公司 一种格隆溴铵化合物
ES2761325T3 (es) 2017-07-17 2020-05-19 Dr August Wolff Gmbh & Co Kg Arzneimittel Emulsión de aceite en agua
KR20200091395A (ko) * 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법
JP2021532112A (ja) 2018-07-24 2021-11-25 ドクトア・アウグスト・ボルフ・ゲーエムベーハー・ウント・コンパニー・カー・ゲー−アルツナイミツテル 抗コリン性化合物の局所用エマルション
CN113784641A (zh) 2019-04-10 2021-12-10 奥古斯特·沃夫博士制药有限及两合公司 用于皮肤施用药物和/或化妆品组合物的系统
JP2022554264A (ja) * 2019-11-05 2022-12-28 ジャーニー メディカル コーポレーション 医薬組成物の手掌又は足底投与のための方法
CN111349036B (zh) * 2020-03-13 2022-03-08 安徽恒星制药有限公司 一种格隆溴铵的替代物及其制备方法和医药用途
TW202245748A (zh) 2021-02-05 2022-12-01 日商三和化學研究所股份有限公司 包含吡咯醣･水楊酸鹽之藥品
CN116887825A (zh) 2021-02-05 2023-10-13 株式会社三和化学研究所 含有格隆铵·水杨酸盐的药物
EP4260852A1 (en) 2022-04-14 2023-10-18 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating
US20250255794A1 (en) 2022-04-14 2025-08-14 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2570433A (en) 1949-08-09 1951-10-09 Gen Tire & Rubber Co Injection molding machine
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
IL22666A (en) 1964-01-06 1968-10-24 Robins Co Inc A H Compositions for inhibiting perspiration containing an 1,1-dialkyl-3-hydroxy-pyrrolidinium ester of an alpha-phenyl-alpha-cycloalkyl-clycolic or acetic acid
US4372098A (en) 1975-12-11 1983-02-08 Mason Keller Corporation Method of making an applicator package
KR840002646A (ko) 1981-12-09 1984-07-16 고니시 진우에몬 구급용 반창고
FR2569689B1 (fr) 1984-09-05 1990-11-16 Oreal Nouveaux derives du benzonorbornene, leurs procedes de preparation et compositions medicamenteuse et cosmetique les contenant
US5008111A (en) 1984-10-11 1991-04-16 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
US4824676A (en) 1984-10-11 1989-04-25 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
IL76635A0 (en) 1984-10-11 1986-02-28 Key Pharma Physiological means of enhancing transdermal delivery of drugs
US4885282A (en) 1987-07-02 1989-12-05 Thornfeldt Carl R Treatment of hyperhidrosis, ichthyosis and wrinkling
US4983395A (en) 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4891228A (en) 1988-02-02 1990-01-02 Richardson-Vicks Inc. Medicated cleansing pads
US4891227A (en) 1988-02-02 1990-01-02 Richardson-Vicks Inc. Medicated cleansing pads
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
ES2153360T3 (es) 1991-05-29 2001-03-01 Abbott Lab Compuestos de isoxazol e de isotiazol que mejoran las funciones de razonamiento.
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH0776230B2 (ja) 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
WO1993021899A1 (en) 1992-05-05 1993-11-11 The Procter & Gamble Company Acne treating composition
US5370917A (en) 1992-06-10 1994-12-06 Fuji Photo Film Co., Ltd. Magnetic recording disc comprising magnetic powder and a binder in a container which includes a nonwoven fabric liner comprising polypropylene and rayon fibers
FI950345A7 (fi) 1992-07-27 1995-01-26 Procter & Gamble Laminoituja kaksoisteksturoituja hoitotyynyjä
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
SE9302218D0 (sv) 1993-06-28 1993-06-28 Ab Astra New use
US5460820B1 (en) 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
JP3688293B2 (ja) 1993-09-29 2005-08-24 アルザ・コーポレーション モノグリセリド／乳酸エステル透過促進剤
US5403588A (en) 1993-11-23 1995-04-04 Santa Ana, Jr.; Cesareo T. Disposable body deodorant pad and deodorant preparation therefor
US5641507A (en) 1993-12-06 1997-06-24 Devillez; Richard L. Delivery system for dermatological and cosmetic ingredients
US5472958A (en) 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5575047A (en) 1994-11-25 1996-11-19 Athena Medical Corporation Method for making biodegradable absorbent pads
US5616337A (en) 1995-01-30 1997-04-01 Genta Incorporated Unit dose skin care package
US5525347A (en) 1995-01-31 1996-06-11 Medical University Of South Carolina Composition and methods for treating performance anxiety
CA2225808C (en) 1995-06-30 2002-12-17 Christopher C. Capelli Silver-based pharmaceutical compositions
US6214792B1 (en) 1996-04-12 2001-04-10 David Lew Simon Method for treating acute and severe diarrhea
US5919760A (en) 1996-04-12 1999-07-06 Intensive Narcotic Detoxification Centers Of America, Llc Method for treating acute and severe diarrhea
US6203810B1 (en) 1996-05-31 2001-03-20 The Procter & Gamble Company Breathable perspiration pads having odor control
EP0909172A4 (en) 1996-07-01 1999-06-09 Sepracor Inc METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE WITH ENANTIOMERIC ENRICHED (R, s) -GLYCOPYRROLATE
WO1998000016A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
US6063808A (en) 1996-07-01 2000-05-16 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (S,S)-glycopyrrolate
EP0909163A4 (en) 1996-07-01 1999-06-09 Sepracor Inc METHOD AND MEANS FOR TREATING URINE INCONTINENCE USING THE (S, R) -GLYCOPYRROLATE ENANTIOMER MAINLY
CA2263473C (en) 1996-08-16 2003-04-22 Christopher C. Capelli Silver-based antimicrobial compositions
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
CN100391942C (zh) 1996-11-11 2008-06-04 索佛特克两合公司 对映异构纯的碱性芳基-环烷基-羟基羧酸酯,其制备方法及其在药品中的应用
US6133253A (en) 1996-12-10 2000-10-17 Abbott Laboratories 3-Pyridyl enantiomers and their use as analgesics
US5919471A (en) 1996-12-13 1999-07-06 Saferstein; Lowell Substantially anhydrous antiseptic wipes
TW486475B (en) 1996-12-26 2002-05-11 Ube Industries Acid addition salt of optically active piperidine compound and process for preparing the same
US5733912A (en) 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
EP0991404A1 (en) 1997-06-24 2000-04-12 Schering-Plough Healthcare Products, Inc. Device for delivery of dermatological ingredients
US6036964A (en) 1998-03-05 2000-03-14 Colgate-Palmolive Company Personal hygiene product with enhanced fragrance delivery
SE9801704D0 (sv) 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
JP2002518414A (ja) 1998-06-22 2002-06-25 ザ、プロクター、エンド、ギャンブル、カンパニー 処理を施した拭き取り用品
US6358516B1 (en) 1998-08-21 2002-03-19 Norris R. Harod One-step system for cleansing, conditioning, and treating the skin
US6395757B1 (en) 1998-08-31 2002-05-28 Arthur M. Bobrove Method for treating hot flashes in humans
US5962505A (en) 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans
US5996797A (en) 1998-08-31 1999-12-07 Chesebrough-Pond's Usa Co. Division Of Conopco, Inc. Towelette pouches with outer container or saddle
US5976499A (en) 1998-09-04 1999-11-02 Johns Hopkins University Macroscopic sweat test for cystic fibrosis
US6346153B1 (en) 1998-12-17 2002-02-12 Kimberly-Clark Worldwide, Inc. Wet or dry web dispenser
WO2000045797A1 (en) 1999-02-02 2000-08-10 Ortho-Mcneil Pharmaceutical, Inc. Method of manufacture for transdermal matrices
US6433003B1 (en) * 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
ES2332749T3 (es) 1999-05-19 2010-02-11 THE PROCTER & GAMBLE COMPANY Articulo absorbente con composicion para el cuidado de la piel.
US6723428B1 (en) 1999-05-27 2004-04-20 Foss Manufacturing Co., Inc. Anti-microbial fiber and fibrous products
WO2001008681A1 (en) 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
GB9918760D0 (en) 1999-08-09 1999-10-13 Darwin Discovery Ltd Topical treatment
US6716805B1 (en) 1999-09-27 2004-04-06 The Procter & Gamble Company Hard surface cleaning compositions, premoistened wipes, methods of use, and articles comprising said compositions or wipes and instructions for use resulting in easier cleaning and maintenance, improved surface appearance and/or hygiene under stress conditions such as no-rinse
US6790435B1 (en) 1999-10-01 2004-09-14 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Antiperspirant compositions comprising microemulsions
US6114346A (en) 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
WO2001035883A1 (en) 1999-11-19 2001-05-25 Xel Herbaceuticals Transdermal delivery system for alkaloids of aconitum species
JP2003513997A (ja) 1999-11-19 2003-04-15 ザ、プロクター、エンド、ギャンブル、カンパニー 定義された浸出値を示す親水性のコンディショニング剤を含むパーソナルケア物品
US6074630A (en) 1999-11-23 2000-06-13 Devillez; Richard L. Delivery system for suncare products
US6562368B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US7358204B2 (en) 2000-04-13 2008-04-15 The Procter And Gamble Company Soft, thick, non-linting nonwoven
GB0015617D0 (en) 2000-06-26 2000-08-16 Vectura Ltd Improved preparations for dermal delivery of active substances
AR032758A1 (es) 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
US6446795B1 (en) 2000-07-31 2002-09-10 The Gillette Company Towelette packaging
US6471986B1 (en) 2000-07-31 2002-10-29 Schering Plough Healthcare Products, Inc. Corn, callus and wart removing pads
GB0019055D0 (en) 2000-08-03 2000-09-27 Unilever Plc Antiperspirant and deodorant products and methods for their use
WO2002020817A1 (en) 2000-09-01 2002-03-14 Fujisawa Pharmaceutical Co., Ltd. A method of producing fr901228
US20020071859A1 (en) 2000-10-23 2002-06-13 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Towelette product with sunscreen agent
US6743433B2 (en) 2001-07-06 2004-06-01 Nicholas V. Perricone Treatment of acne using alkanolamine compositions
US6436417B1 (en) 2001-06-25 2002-08-20 Blistex Inc. Acne treatment compositions
DE10136404A1 (de) * 2001-07-26 2003-02-20 Johannes Wohlrab Arzneiformulierung zur topischen Anwendung für die Therapie und Prophylaxe von Hyperhidrosis
EP1438001A4 (en) 2001-09-26 2006-03-15 Alison B Lukacsko COMPOSITIONS AND METHODS FOR INHIBITING ECCRINS PERSPIRATION IN HUMANS
US6472563B1 (en) 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US7838447B2 (en) 2001-12-20 2010-11-23 Kimberly-Clark Worldwide, Inc. Antimicrobial pre-moistened wipers
US8252316B2 (en) 2002-05-03 2012-08-28 Purepharm Inc. Method of topically applying glycopyrrolate solution using absorbent pad to reduce sweating
CA2384922C (en) 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
AT412088B (de) 2002-12-18 2004-09-27 Pharmacon Forschung & Beratung Gmbh Verfahren zur herstellung der r,r oder s,s konfigurierten glycopyrronium-isomere
AU2003238664A1 (en) 2003-03-12 2004-09-30 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
WO2004093792A2 (en) 2003-04-18 2004-11-04 Lighthouse Innovations, Llc Compositions and methods for treating body malodor and fungal overgrowth in mammals
ES2413011T3 (es) 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
JP2007524699A (ja) 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト ロフルミラストとグリコピロニウムとの組合せ物
EP1720577A2 (en) 2004-02-27 2006-11-15 Altana Pharma AG Ciclesonide and glycopyrronium combination
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CA2568834A1 (en) 2004-06-29 2006-01-12 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and an anticholinergic
EP1616567A1 (en) 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
WO2006069998A2 (de) 2004-12-27 2006-07-06 Beiersdorf Ag Glycopyrrolat in kosmetischen zubereitungen
GB0504463D0 (en) 2005-03-03 2005-04-13 Arakis Ltd Method of crystallisation and purification
EP1863476B1 (en) 2005-03-16 2016-02-03 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
US7915303B2 (en) 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0611240D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
WO2008002683A2 (en) 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Polymorphous forms of carvedilol phosphate
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
US20080292560A1 (en) 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
JP2010530902A (ja) 2007-06-22 2010-09-16 サイエル ファーマ，インコーポレイティド 流涎症治療のためのグリコピロレートを含む経皮送達システム
US20090005577A1 (en) * 2007-06-29 2009-01-01 Nikolai Kraiouchkine Method of producing 1-substituted 3-pyrrolates
WO2009024997A1 (en) 2007-08-21 2009-02-26 Lupin Limited Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer
ES2671874T3 (es) 2007-10-18 2018-06-11 Rose U, Llc Formulaciones tópicas de glicopirrolato
WO2009142589A1 (en) 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
AU2009212902A1 (en) 2008-09-03 2010-03-18 Apotex Pharmachem Inc. Amorphous form of an L-arginine salt of perindopril and processes of preparation thereof
ES2617680T3 (es) * 2009-04-09 2017-06-19 Novartis Ag Proceso para la preparación de sales de pirrolidinio
RU2569852C2 (ru) 2010-06-14 2015-11-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Кристаллическая форма гликопиррония хлорида
EP2580194A1 (en) 2010-06-14 2013-04-17 Chiesi Farmaceutici S.p.A. Process for the preparation of glycopyrronium chloride
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) * 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩

Also Published As

Publication number Publication date
MX2015011228A (es) 2015-11-13
JP6114841B2 (ja) 2017-04-12
EP2961734B1 (en) 2018-09-26
US20170157088A1 (en) 2017-06-08
EP3842419A1 (en) 2021-06-30
AU2016269524A1 (en) 2017-01-05
CA2902795C (en) 2021-06-15
JP2016510037A (ja) 2016-04-04
JP2017128593A (ja) 2017-07-27
ES2699257T3 (es) 2019-02-08
CA2902795A1 (en) 2014-09-04
KR20190138676A (ko) 2019-12-13
US10004717B2 (en) 2018-06-26
KR20150119468A (ko) 2015-10-23
WO2014134510A1 (en) 2014-09-04
EP3842419B1 (en) 2024-04-03
US20190133999A1 (en) 2019-05-09
AU2016269524B2 (en) 2018-09-13
EP3473615B1 (en) 2022-01-19
CN105026369A (zh) 2015-11-04
KR102377252B1 (ko) 2022-03-22
US9610278B2 (en) 2017-04-04
KR20210034691A (ko) 2021-03-30
AU2014223172B2 (en) 2016-09-08
IL240684A0 (en) 2015-10-29
IL240684A (en) 2016-02-29
HK1212350A1 (en) 2016-06-10
SG11201506789PA (en) 2015-09-29
AU2014223172A1 (en) 2015-08-20
US10548875B2 (en) 2020-02-04
US20180271833A1 (en) 2018-09-27
ES2981043T3 (es) 2024-10-07
IL317757A (en) 2025-02-01
IL278152A (en) 2020-11-30
US20160113902A1 (en) 2016-04-28
KR102232806B1 (ko) 2021-03-29
NZ710740A (en) 2020-06-26
EP3473615A1 (en) 2019-04-24
EP2961734A1 (en) 2016-01-06
US10543192B2 (en) 2020-01-28
KR20160081989A (ko) 2016-07-08
JP6379246B2 (ja) 2018-08-22

Similar Documents

Publication Publication Date Title
MX2020002544A (es) Sales de glicopirrolato.
MX389228B (es) Composiciones para tratar el cabello.
MX375786B (es) Biosintesis microbiana de ergotioneina.
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
MX2015012334A (es) Metodos y composiciones para el control de malezas.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
EP3082819A4 (en) Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
PH12016500598A1 (en) Protoxin-ii variants and methods of use
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX367393B (es) Composiciones antifungicas para el tratamiento de piel y uñas.
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
MX381841B (es) Anticuerpos anti-jagged y métodos de uso.
MX358132B (es) Solucion de trombina y metodos de uso de esta.
WO2014146111A3 (en) Analgesic compounds and methods of use
MX2015013021A (es) 5-bromo-indirrubinas.
IN2014DN07191A (es)
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy